Background and Aim: Type 2 Diabetes Mellitus (T2DM) is a growing global concern driven by genetic, lifestyle, and environmental factors. Risk factors such as obesity, sedentary behavior, and poor diet worsen its progression, leading to complications. Combination therapy offers superior glycemic control by targeting multiple pathophysiological processes, preserving β-cell function, and reducing complications. This cross-sectional observational survey aims to evaluate the clinical experience, effectiveness, safety, and tolerability of the sitagliptin + dapagliflozin + metformin sustained-release (SR) fixed-dose combination (FDC) in the management of T2DM. Materials and Methods: A total of 450 clinicians, including endocrinologists, diabetologists, and general practitioners, participated in the survey. Descriptive statistics were applied, with categorical variables presented as percentages. Graphical representations were created using Microsoft Excel 2024. Results: Key findings revealed that the majority of clinicians ( n = 367; 82%) perceived the triple-drug FDC to be more effective in achieving glycated hemoglobin targets compared to traditional sequential therapy. Cardiovascular (CV) safety was rated highly by 96% ( n =432) of clinicians. Furthermore, 41% ( n = 184) reported that the therapy was well-tolerated by patients, and 54% ( n = 244) reported that the therapy was well-tolerated with occasional mild side effects. The combination was found to be particularly beneficial for patients with uncontrolled diabetes, CV risk factors, and a high pill burden. Conclusions: These findings demonstrate the positive real-world impact of the triple-drug FDC sitagliptin + dapagliflozin + metformin SR tablets on T2DM management. However, the survey’s observational nature, potential selection bias, and reliance on self-reported data may limit the generalizability of the results.
Manoj Suva (Thu,) studied this question.